| Literature DB >> 33929659 |
Donal O'Shea1, Scott Kahan2, Lorna Lennon, Cathy Breen3.
Abstract
Obesity is a chronic and treatable disease carrying risk for numerous health complications, including cardiovascular disease, respiratory disease, type 2 diabetes mellitus and certain cancers. While there is a great need to address the topic in clinical practice, healthcare professionals (HCPs) often struggle to initiate conversations about weight. In this paper, guidance on how to raise and address the subject of weight with individuals is provided from an HCP and patient perspective using the 5As framework. This model facilitates advising individuals on the benefits of weight loss and supports them to develop achievable and sustainable weight management plans. With obesity rates still rising across the globe, it is imperative that more HCPs become skilled in raising and addressing the issue.Entities:
Keywords: Counselling; Obesity; Patient view
Year: 2021 PMID: 33929659 PMCID: PMC8085475 DOI: 10.1007/s12325-021-01748-0
Source DB: PubMed Journal: Adv Ther ISSN: 0741-238X Impact factor: 3.845
Summary of common obesity-related complications
| Increased risk for | Evidence |
|---|---|
| T2D [ | 1.5-fold increased risk with BMI of 25.0–29.9 kg/m2 5 times increased risk with BMI of ≥ 40 kg/m2 Elevated risk in Asian population due to greater prevalence of visceral versus peripheral adiposity compared with Caucasian population |
| CVD [ | Greater waist circumference associated with development of disease Risk of premature death from CVD caused by high BMI is increased 2–3-fold in people with obesity |
| NAFLD [ | Obesity is most significant risk factor Positive correlation between BMI and disease severity |
| OA [ | Weight is greatest modifiable risk factor |
| OSA [ | > 10-fold increased risk with BMI > 29.0 kg/m2 |
| GORD [ | 1.4-fold increased risk with BMI of 25.0–30 kg/m2 1.9-fold increased risk with BMI of ≥ 30 kg/m2 |
| Cancer [ | Strong evidence for increased cancer risk related to excess body weight across colorectal, oesophageal, kidney and pancreatic cancers across both sexes Strong evidence for increased risk of endometrial cancer and post-menopausal breast cancer in women |
| Depression [ | People with obesity have 55% increased risk of developing depression |
CVD cardiovascular disease, GORD gastroesophageal reflux disorder, NAFLD non-alcoholic fatty liver disease, OA osteoarthritis, OSA obstructive sleep apnoea, T2D type 2 diabetes.
Fig. 1Health benefits of a 5–10% weight loss. a Detailed summary of health benefits that can be achieved with a 5–10% weight loss from baseline including quantitative/measurable benefits on cardiometabolic and glycaemic parameters, and life expectancy. b Simplified version of the health benefits that are achievable with a 5–10% weight loss, in patient-friendly language. HDL high-density lipoprotein, LDL low-density lipoprotein, BP blood pressure, HbA1C haemoglobin A1c, T2DM type 2 diabetes mellitus; *with 10 kg weight loss; †in individuals who have undergone bariatric surgery. References: 1 Wing RR, et al. Diabetes Care. 2011; 34: 1481–6. 2 Van Gaal L, et al. Eur Heart J 2005; 7: 21–6. 3 Aucott L, et al. Hypertension. 2005; 45: 1035–41. 4 Lindstrom J, et al. Diabetes Care 2003; 26: 3230–6. 5 Tuomilehto et al. N Engl J Med 2001; 344: 1343–50. 6 Luo J, et al. Oncotarget 2017; 8: 81,719–720. 7 Tee MC, et al. Surg Endosc. 2013; 24: 4449–56. 8 National Cancer Institute: Obesity and Cancer Available at: https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet, accessed 25 September 2019. 9 Kritchevsky SB, et al. PLoS ONE 2015; 10: e0121993
Fig. 2Guidance on level of intervention to consider [5, 40–45, 59]. BMI body mass index (reported in kg/m2). Consult local guidelines for specific recommendations. *In some non-Asian regions, people with type 2 diabetes can be considered
Summary of dosing regimens of available and investigational weight management pharmacotherapies
| Route of administration | Dose | |
|---|---|---|
| Oral | Prescription: 120 mg three times daily OTC: 60 mg three times daily | |
| Oral | Up to 15 mg/92 mg daily | |
| Subcutaneous | 3 mg daily | |
| Oral | Up to 32 mg/360 mg daily | |
| Subcutaneous | 2.4 mg daily |
Weight management agents should always be used in conjunction with appropriate behavioural interventions
aSemaglutide is an investigational product and has not been approved by the FDA or EMA at the time of writing
| Obesity is chronic and treatable, and confers risk for numerous health conditions including cardiovascular disease, type 2 diabetes and, more recently, severe COVID-19; however, despite this, global incidence is rising. |
| As such, there is a pressing need to address it in clinical practice; however, healthcare professionals often struggle to initiate conversations about weight. |
| This paper provides guidance on how to sensitively and effectively address the topic of weight from the perspective of both a healthcare professional and people living with obesity through use of the 5As framework. |
| The 5As framework for tackling obesity in clinical settings was described in detail, with relevant examples. |
| While primary care physicians are central to managing obesity, a multidisciplinary approach involving all care providers should be utilised to consider environmental and psychosocial influences impacting obesity, and to address psychological and physiological challenges associated with achieving and sustaining long-term weight loss. |
| The 5As framework is transferable across disciplines. |